-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: Diabetes mellitus is associated with a faster decline in renal function in patients with heart failure (HF)
.
Sacubitril/valsartan attenuated worsening of renal function with reduced ejection fraction in patients with diabetes and heart failure to a greater extent than renin-angiotensin system inhibitors alone
Diabetes is associated with a faster decline in kidney function in patients with heart failure (HF)
interaction _
Figure 1.
Effects of sacubitril/valsartan (SAC/Val) on time-dependent changes in glomerular filtration rate (EGFR) and composite renal outcomes in diabetic and non-diabetic patients
.
Adjusted means for EGFR over 192 weeks were obtained from a repeated-measures mixed-effects model
Figure 1.
Table 1 Estimated rate of glomerular filtration rate decline from baseline (ml/min/1.
73m2/year)
73m2/year)
Figure 2 Changes in estimated glomerular filtration rate (EGFR) over time in diabetic and nondiabetic patients
.
Adjusted means for EGFR over 192 weeks were obtained from a repeated-measures mixed-effects model
Figure 2 Changes in estimated glomerular filtration rate (EGFR) over time in diabetic and nondiabetic patients
Figure 3 Kaplan-Meier analysis of the effect of diabetes status on comprehensive renal prognosis
.
Probability of first occurrence of composite renal outcome (estimated glomerular filtration rate reduction from baseline by 50%, development of end-stage renal disease, or death attributable to renal causes) obtained from Kaplan-Meier failure analysis ≥50% reduction in estimated glomerular filtration rate from baseline, development of end-stage renal disease, or death attributable to renal causes)
Figure 3 Kaplan-Meier analysis of the effect of diabetes status on comprehensive renal prognosis
Table 3.
Composite renal outcomes and their individual components
Composite renal outcomes and their individual components
Figure 4 Combined renal outcomes (estimated 50% reduction in glomerular filtration rate from baseline, development of end-stage renal disease or death attributable to renal causes)
.
Estimated rate ratios and 95% confidence intervals were obtained using a negative binomial regression model for HbA1c with restricted cubic splines
Figure 4 Combined renal outcomes (estimated 50% reduction in glomerular filtration rate from baseline, development of end-stage renal disease or death attributable to renal causes)
Figure 4 Effect of T treatment with sacubitril/valsartan versus valsartan on the composite renal outcome (estimated glomerular filtration rate reduction [eGFR] ≥50% relative to baseline, end-stage renal disease development, or death from renal causes)
.
Estimated ratios and 95% confidence intervals were obtained from negative binomial regression models, and baseline eGFR was expressed by restricted cubic splines
.
Figure 4 Effect of T treatment with sacubitril/valsartan versus valsartan on the composite renal outcome (estimated glomerular filtration rate reduction [eGFR] ≥50% relative to baseline, end-stage renal disease development, or death from renal causes)
.
Estimated ratios and 95% confidence intervals were obtained from negative binomial regression models, and baseline eGFR was expressed by restricted cubic splines
.
Conclusions: Compared with valsartan, sacubitril/valsartan attenuated the decline in eGFR and reduced clinically relevant renal events in HFpEF patients with and without diabetes
.
.
Original source: Peikert A, Vaduganathan M, McCausland F, et al.
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF .
Eur J Heart Fail 2022 Feb 04